

Angelo Belotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2690257/publications.pdf>

Version: 2024-02-01

9
papers

225
citations

1162889
8
h-index

1474057
9
g-index

9
all docs

9
docs citations

9
times ranked

679
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. <i>Cancer</i> , 2020, 126, 5069-5076.	2.0	69
2	Peripheral Blood Lymphocyte/Monocyte Ratio Predicts Outcome in Follicular Lymphoma and in Diffuse Large B-Cell Lymphoma Patients in the Rituximab Era. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 208-213.	0.2	35
3	Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab. <i>Blood Cancer Journal</i> , 2021, 11, 151.	2.8	32
4	Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-GRADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry. <i>Cancer Medicine</i> , 2021, 10, 5859-5865.	1.3	22
5	Circulating endothelial cells and endothelial activation in essential thrombocythemia: Results from CD146 ⁺ immunomagnetic enrichment flow cytometry and soluble E-selectin detection. <i>American Journal of Hematology</i> , 2012, 87, 319-320.	2.0	18
6	Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: Kinetics of its appearance and potential predictive role in infectious complications. <i>Leukemia Research</i> , 2015, 39, 88-91.	0.4	18
7	Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years. <i>American Journal of Hematology</i> , 2020, 95, 759-765.	2.0	16
8	Circulating microRNAs and Their Role in Multiple Myeloma. <i>Non-coding RNA</i> , 2019, 5, 37.	1.3	10
9	Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. <i>Blood Cancer Journal</i> , 2021, 11, 197.	2.8	5